Allogeneic transplantation across the HLA barriers.

摘要: In high-risk acute leukemia patients, a 10-fold increase in the dose of extensively T-cell-depleted hematopoietic stem cells ensures sustained full-donor engraftment one-haplotype-mismatched transplants without graft-vs.-host disease. Since our first successful pilot study, which exploited principle megadose cell transplant, efforts have concentrated on developing new conditioning regimens, optimizing graft processing and improving post-transplant immunologic recovery. The results so far achieved more than 100 patients show that haploidentical transplantation is now clinical reality. Because virtually all need transplant full-haplotype-mismatched family donor, mismatched can be offered with curative intent, thus extending allogeneic procedures to candidates.